News

Lanchi Ventures Invests in Allink Biotherapeutics' Growth Plans

Lanchi Ventures Invests in Allink Biotherapeutics' Growth Plans

Lanchi Ventures Invests in Allink Biotherapeutics' Growth Plans

The recent Series A investment round has successfully secured resources essential for advancing global clinical programs and expanding the footprint of Allink Biotherapeutics.

Allink Biotherapeutics Completes $42 Million Financing

Allink Biotherapeutics, a clinical-stage biotechnology firm known for its pioneering work in bispecific antibodies and antibody-drug conjugates (ADCs), recently announced the completion of its $42 million Series A financing. Lanchi Ventures played a pivotal role in leading this financing round, renowned for its support of groundbreaking innovations. The round also welcomed participation from a notable syndicate of new investors including Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment, alongside robust backing from existing shareholders such as Gaorong Ventures and Med-Fine Capital.

Accelerating Development with Strategic Investments

Dr. Hui Feng, the founder and CEO of Allink Bio, expressed his gratitude towards both existing and new investors for their support, emphasizing the significance of this financing for the company's continued advancement. The funds are set to propel the development of a diverse pipeline featuring next-generation ADCs and bispecific antibodies, specifically targeting oncology and immunology indications. With this financial backing, Allink intends to reach critical milestones in the coming months, reflecting its mission to introduce innovative therapeutics aimed at addressing significant unmet medical needs.

Innovative Approaches in Antibody Development

Lanchi Ventures highlighted the impressive speed and quality with which AllinkBio has advanced its lead program from a preclinical stage to clinical development. Under the adept leadership of Dr. Feng, a prominent figure in the biopharmaceutical sector, the company's competitiveness in the field is distinctly showcased. Lanchi Ventures noted that AllinkBio's innovative strategies in ADC development offer compelling prospects within targeted oncology therapeutics.

Deployment of Series A Financing Proceeds

The proceeds from the Series A financing will be strategically employed to:

  • Advance the global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies.
  • Enrich the existing portfolio by developing multiple competitive new assets in oncology and immunology.
  • Further develop the proprietary bispecific antibody and ADC technology platform.
  • Expand the global footprint to attain world prominence.

AllinkBio's Growth Trajectory

The successful conclusion of this financing round marks a significant moment for AllinkBio, providing the necessary capital to enhance its growth trajectory. With these resources, combined with the company's strong R&D capabilities, AllinkBio is poised for accelerated advancement on both product and corporate fronts.

About Allink Biotherapeutics

Founded in recent years, Allink Biotherapeutics is a clinical stage biotechnology entity committed to leveraging its innovative proprietary platforms to bring forth a diverse pipeline comprising First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. The company focuses on developing groundbreaking medications in oncology and immunology, addressing critical unmet medical needs worldwide.

About Lanchi Ventures

Lanchi Ventures (LCV) is a prominent early-stage venture capital firm with a reach extending across Southeast Asia. Specializing in investments that harness technological innovation for sustainable impact, Lanchi Ventures has cultivated a rich heritage in Silicon Valley since 1998. Managing over $2 billion across multiple funds, Lanchi Ventures has made investments in over 200 companies, including notable names like Gaussian Robotics and Li Auto (NASDAQ: LI). The firm has garnered recognition from various prestigious organizations.

Frequently Asked Questions

What is the focus of Allink Biotherapeutics?

Allink Biotherapeutics is focused on developing next-generation bispecific antibodies and ADCs to treat oncology and immunology-related diseases.

Who led the recent Series A financing for Allink Biotherapeutics?

Lanchi Ventures led the $42 million Series A financing for Allink Biotherapeutics.

What will the Series A financing funds be used for?

The funds will be used for clinical development, expanding the portfolio, and enhancing the ADC technology platform.

What is the significance of this financing for Allink Biotherapeutics?

This financing represents a pivotal point in Allink's growth, allowing for accelerated development of its therapeutic pipeline.

What is Lanchi Ventures known for?

Lanchi Ventures is recognized for backing breakthrough innovations and supporting early-stage technology firms with significant growth potential.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 157

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 70

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 192

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 147

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Analysis of Strategy Inc's Recent Stock Performance

Updated Category News Views 143

Strategy Inc (NASDAQ: MSTR) Faces Critical Trading Challenges Strategy Inc stock recently closed at $300.70, marking a notable decline of approximately 7%. This downturn has positioned the stock at a pivotal moment in its trading journey, stirring discussions among analysts and investors alike. Technical Analysis Reveals Breakdown Risks Following a series of downward...

Continue Reading
Major Bank Stock Opportunities Following Fed's Rate Reductions

Updated Category News Views 77

Major Bank Stock Opportunities Following Fed's Rate Reductions The recent cut in interest rates by the Federal Reserve marks a crucial shift in the banking industry, especially for mid- and small-cap banks. With a reduction of 50 basis points, this decision indicates a new phase that could improve profitability across the banking sector. Analyst Steven Alexopoulos at...

Continue Reading
SafeRent Resolves Discrimination Lawsuit with $2.3M Settlement

Updated Category News Views 519

SafeRent Settles Discrimination Lawsuit for $2.3 Million SafeRent Solutions, a leading AI-driven tenant screening service, has successfully settled a class action lawsuit aimed at its screening practices. The case, filed in a Massachusetts court, raised significant concerns regarding the treatment of low-income renters. Details of the Settlement Recently, U.S. District...

Continue Reading
Medical Experts Rally Behind RFK Jr. for HHS Leadership

Updated Category News Views 496

Support from Medical Professionals for RFK Jr. Leadership In a compelling demonstration of support, more than 800 medical professionals have signed a letter endorsing Robert F. Kennedy Jr. for the position of Secretary of Health and Human Services (HHS). This unified action showcases the broad consensus among healthcare leaders that significant reforms are essential to...

Continue Reading
Lundin Gold's Exploration Uncovers Exceptional Porphyry Grades

Updated Category News Views 169

Exciting Developments in Exploration for Lundin Gold Lundin Gold Inc. (TSX: LUG) has made remarkable progress in its exploration activities at the Fruta del Norte (FDN) gold mine, revealing outstanding porphyry mineralization that showcases significant copper and gold potential. The mining company is currently focusing its efforts on three areas of interest: Sandia,...

Continue Reading